A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Part of paid clinical trials in Madera, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07300267
Phase
PHASE1
Status
Recruiting

Conditions

  • Pneumococcal Infection

Eligibility Criteria

Sex
ALL
Age
2 Months - 15 Months
Healthy Volunteers
Accepted

Interventions

  • V118C (Stage 1) — BIOLOGICAL
    IM administration of V118C
  • V118C (Stage 2) — BIOLOGICAL
    IM administration of V118C
  • PCV20 (Stage 1) — BIOLOGICAL
    IM administration of PCV20
  • PCV20 (Stage 2) — BIOLOGICAL
    IM administration of PCV20

Study Details

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Key Dates

Start date
Jan 13, 2026
Status verified
Apr 2026
Primary completion
Oct 24, 2028
Completion
May 25, 2029

Study Design

Enrollment
210 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: V118C (Stage 1)
    Participants will receive a single 0.5 mL intramuscular (IM) injection of V118C administered at 12 to 15 months of age.
  • Experimental: V118C (Stage 2)
    Participants will receive a single 0.5 mL IM injection of V118C administered at 2,4,6, and 12 months of age.
  • Active Comparator: PCV20 (Stage 1)
    Participants will receive a single 0.5 mL IM injection of PCV20 administered at 12 to 15 months of age.
  • Active Comparator: PCV20 (Stage 2)
    Participants will receive a single 0.5 mL IM injection of PCV20 administered at 2,4,6, and 12 months of age.

Primary Outcome Measure

Stage 1: Percentage of Participants With Immediate Adverse Events (AEs) Following Vaccination [ Time Frame: Up to approximately 30 minutes postvaccination ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Madera Family Medical Group ( Site 1004)MaderaCalifornia93637
Study Coordinator
559-673-3000
Acevedo Clinical Research Associates ( Site 1029)MiamiFlorida33142
Study Coordinator
305-649-8871
University of South Florida-Department of Pediatrics ( Site 1002)TampaFlorida33606
Study Coordinator
813-821-8039
Cotton O'Neil Research Center ( Site 1039)TopekaKansas66604
Study Coordinator
785-354-6000
University of Louisville, Norton Children's Research Institute ( Site 1005)LouisvilleKentucky40202
Study Coordinator
502-629-5820
The Pediatric Center ( Site 1025)ColumbiaMaryland21045
Study Coordinator
443-721-7224
Saint Louis University Center for Vaccine Development ( Site 1031)St LouisMissouri63104
Study Coordinator
314-977-6333
Child Health Care Associates ( Site 1035)East SyracuseNew York13057
Study Coordinator
315-652-8800
Tribe Clinical Research, LLC-Pediatrics ( Site 1008)GreenvilleSouth Carolina29607
Study Coordinator
864-334-0141
Tribe Clinical Research - Spartanburg ( Site 1001)SpartanburgSouth Carolina29301
Study Coordinator
864-334-0141
Epic Medical Research - Carrollton ( Site 1038)CarrolltonTexas75006
Study Coordinator
972-777-6956
Epic Medical Research- Garland ( Site 1017)GarlandTexas75043
Study Coordinator
972-777-6956
University of Texas Medical Branch ( Site 1020)League CityTexas77573
Study Coordinator
832-340-2313
Pediatric Research of Charlottesville, LLC ( Site 1012)CharlottesvilleVirginia22902
Study Coordinator
434-872-9384

Find similar trials in Madera, CA